MediciNova says Phase 2 MN-001 trial in NAFLD with type 2 diabetes misses primary endpoints
MNOV•MediciNova said its Phase 2 MN-001 trial in NAFLD with high triglycerides tied to type 2 diabetes missed its primary endpoints, though it showed favorable signals on cholesterol-related measures.
1. Trial results
MediciNova reported that the Phase 2 study showed favorable signals on cholesterol-related measures, while effects on other disease indicators were mixed and fell short of primary goals. MN-001 was well tolerated, with no drug-related serious adverse events reported; further analyses are underway. The company expects topline results from its COMBAT-ALS trial of MN-166 in ALS by year-end.
